Dade’s New Dimension: In Hospital Cost-Cutting Environment, Size Matters
This article was originally published in The Gray Sheet
Executive Summary
Dade Behring anticipates launching a next-generation Dimension integrated chemistry analyzer system in "high-volume" laboratories in 2005, targeting a $5 bil. worldwide market
You may also be interested in...
Dade Behring goes public
Diagnostics firm completes pre-packaged Chapter 11 debt restructuring and enters the public market with a new board of directors Oct. 3. The firm expects to complete Nasdaq registration within six months; common equity initially will be traded over-the-counter, with prices listed in the pink sheets. In August, Dade Behring announced a debt-to-equity swap to cover $1.5 bil. in liabilities for the company, then privately held (1"The Gray Sheet" Aug. 5, 2002, p. 16)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.